Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
NCT ID: NCT03488550
Last Updated: 2020-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
9 participants
INTERVENTIONAL
2018-03-23
2018-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
NCT00705770
A Phase I Clinical Trial of DARC
NCT02394613
Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle Glaucoma
NCT05892185
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT06964061
Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes
NCT05506423
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ANX007-GLA-01
ANX007
Single ascending dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANX007
Single ascending dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of primary open-angle glaucoma
* Intraocular pressure \<21 mm Hg on a stable IOP treatment regimen
* Reliable visual field testing
Exclusion Criteria
* Extensive glaucomatous visual-field damage
* History of intraocular inflammatory or infectious eye disease in study eye
* Ocular trauma in study eye within the preceding 6 months
* History of uncomplicated cataract surgery less than 6 mos prior
* Any abnormality preventing reliable Tonopen tonometry in study eye
* Active malignancy within past 5 yrs
* Previous tx with another humanized monoclonal antibody
* History of any autoimmune or neurologic disease
* Concurrent use of glucocorticoid medications
* Receiving monoamine oxidase inhibitor therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Annexon, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Humphriss
Role: STUDY_DIRECTOR
Annexon Vice President of Clinical Operations
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eye Research Foundation
Newport Beach, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANX007-GLA-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.